Dataset Information


Breast cancer cell lines treated with EZH2 inhibitor compounds

ABSTRACT: Loss of H3K27me3 repressive chromatin histone marks, maintained by the histone methyltransferase (HKMT) EZH2, may lead to reversal of epigenetic silencing in tumor cells and have therapeutic potential. Using a cell-based assay, we have identified three compounds from a HKMT inhibitor chemical library which re-express H3K27me3 mediated, silenced genes. Chromatin immunoprecipitation verified a decrease in silencing marks (H3K27me3, H3K9me3) and importantly an increase in active marks (H3K4me2/3, H3K27ac) at the promoter of re-expressed genes. Compound treated breast tumor cells induced enrichment for genome-wide changes in expression of known target genes for EZH2 and induced cell growth inhibition: with most sensitive breast tumor cell lines having low EZH2 protein expression, while a normal epithelial breast line was least sensitive. Agilent SurePrint G3 Human 8x60k two-colour microarrays were used to profile gene expression changes induced by treatment with drug compounds in MDA MB-231 cells, both at 24h and 48h. 4 replicates were used for each drug, time combination. A separate untreated control sample was used for comparison with each replicate.

ORGANISM(S): Homo sapiens  

SUBMITTER: Robert Brown   Ed Curry 

PROVIDER: E-GEOD-36131 | ArrayExpress | 2013-08-27



Similar Datasets

2012-11-01 | E-GEOD-36905 | ArrayExpress
2018-07-03 | PXD010073 | Pride
2013-12-31 | E-GEOD-52016 | ArrayExpress
2013-05-13 | E-GEOD-45982 | ArrayExpress
2018-04-25 | PXD008076 | Pride
2012-03-15 | E-GEOD-29992 | ArrayExpress
2013-06-20 | E-GEOD-45579 | ArrayExpress
2015-07-15 | E-GEOD-59463 | ArrayExpress
2016-08-16 | E-GEOD-85222 | ArrayExpress
2014-07-01 | E-GEOD-54029 | ArrayExpress